Follow the オンコリスバイオファーマ株式会社 share price and the full management transaction log of the company, a listed equity based in Japan. Shares trade on JP JP, under the oversight of EDINET (Japan FSA). Market capitalisation: €72.9bn. The latest transaction was disclosed on 5 February 2026 (Holding update). Among the most active insiders: SMBC Nikko Securities Inc.. The full history is openly available.
31
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
17Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,607 of 28,169 companies
38.7
score / 100
Value
27
Quality
51
FCF yld-2.7%
Earn yld-2.8%
EV/EBITDA·
ROE-110%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Oncolis BioPharma Inc. is a Japanese biopharmaceutical company focused on developing innovative cancer treatments. It specializes in the research and commercialization of therapies based on oncolytic viruses.